{"transactions":[{"id":705441,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-22T00:39:23.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":10826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026."}],"balance_after":10826,"derivative":{"exercise_price":12.64,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":10826},"source":{"system":"sec-edgar","filing":"0001193125-26-310980","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312526310980/ownership.xml","form_type":"4/A","original_submission_date":"2026-06-16"}},{"id":737202,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T20:30:40.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":9810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":9810,"derivative":{"exercise_price":12.64,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":9810},"source":{"system":"sec-edgar","filing":"0001193125-26-272701","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312526272701/ownership.xml","form_type":"4"}},{"id":742429,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:14:03.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":5000,"derivative":{"exercise_price":4.43,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-267558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312526267558/ownership.xml","form_type":"4"}},{"id":927582,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-31T00:00:07.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":23272,"price":2.75,"value":63998.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported."}],"balance_after":23272,"derivative":{"exercise_price":3.6,"expiration_date":"2036-01-14","underlying":"Common Stock","underlying_shares":23272},"source":{"system":"sec-edgar","filing":"0001193125-26-032248","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312526032248/ownership.xml","form_type":"4"}},{"id":936571,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-20T21:16:19.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":520,"price":24,"value":12480.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"520 shares of common stock were granted upon the close of business on January 15, 2026, as consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q4-25."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"520 shares of common stock were granted upon the close of business on January 15, 2026, as consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q4-25."}],"balance_after":7382,"source":{"system":"sec-edgar","filing":"0001104659-26-005043","document":"tm263642-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465926005043/tm263642-2_4seq1.xml","form_type":"4"}},{"id":942828,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T21:30:22.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":690900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":690900,"derivative":{"exercise_price":0.055,"exercise_date":"2026-01-07","expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":690900},"source":{"system":"sec-edgar","filing":"0001213900-26-002947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390026002947/ownership.xml","form_type":"4"}},{"id":949350,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T21:33:43.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock option was granted pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer and has an exercise price of $23.82 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance."}],"balance_after":1500,"derivative":{"exercise_price":23.82,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001104659-26-001350","document":"tm261953-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465926001350/tm261953-6_4seq1.xml","form_type":"4"}},{"id":968568,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":6.4,"expiration_date":"2035-05-26","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968567,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":1100,"derivative":{"exercise_price":5.44,"expiration_date":"2035-05-26","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968566,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":15.364,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968565,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":1100,"derivative":{"exercise_price":5.44,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968564,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":32.6,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968563,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":1250,"derivative":{"exercise_price":5.44,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968562,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reporting person agreed to cancellation of an option granted on December 14, 2022, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":27.2,"expiration_date":"2032-12-13","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968561,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reporting person agreed to cancellation of an option granted on December 14, 2022, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":1250,"derivative":{"exercise_price":5.44,"expiration_date":"2032-12-13","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968560,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":39.8,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968559,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":1250,"derivative":{"exercise_price":5.44,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968558,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":60.6,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968557,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":1250,"derivative":{"exercise_price":5.44,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968556,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1392,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person agreed to cancellation of an option granted on December 29, 2020, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":88.2,"expiration_date":"2030-12-28","underlying":"Common Stock","underlying_shares":1392},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":968555,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:13:46.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1392,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person agreed to cancellation of an option granted on December 29, 2020, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable."}],"balance_after":1392,"derivative":{"exercise_price":5.44,"expiration_date":"2030-12-28","underlying":"Common Stock","underlying_shares":1392},"source":{"system":"sec-edgar","filing":"0001193125-25-321152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525321152/ownership.xml","form_type":"4"}},{"id":1011686,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:33:57.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.6,"expiration_date":"2035-02-01","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0001193125-25-259069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525259069/ownership.xml","form_type":"4"}},{"id":1011685,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:33:57.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.98,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":45150},"source":{"system":"sec-edgar","filing":"0001193125-25-259069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525259069/ownership.xml","form_type":"4"}},{"id":1011684,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:33:57.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":14.7,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0001193125-25-259069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525259069/ownership.xml","form_type":"4"}},{"id":1011683,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:33:57.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.64,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001193125-25-259069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525259069/ownership.xml","form_type":"4"}},{"id":1011682,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:33:57.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":18.68,"expiration_date":"2031-11-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-259069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525259069/ownership.xml","form_type":"4"}},{"id":1013592,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-28T01:16:06.000Z","date":"2025-10-23","kind":"grant","planned":false,"acquired":true,"shares":53521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":53521,"derivative":{"exercise_price":2.8,"expiration_date":"2035-10-22","underlying":"Common Stock","underlying_shares":53521},"source":{"system":"sec-edgar","filing":"0001193125-25-251978","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000119312525251978/ownership.xml","form_type":"4"}},{"id":1018088,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-16T20:33:30.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":711,"price":17.58,"value":12499.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"711 shares of common stock were granted upon the close of business on October 15, 2025, as a consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q3-25."}],"balance_after":6862,"source":{"system":"sec-edgar","filing":"0001104659-25-100109","document":"tm2528907-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465925100109/tm2528907-4_4seq1.xml","form_type":"4"}},{"id":1044451,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-10T20:03:55.000Z","date":"2025-09-08","kind":"sale","planned":false,"acquired":false,"shares":6152,"price":20.06,"value":123409.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were initially granted to the Reporting Person on April 15, 2024 as consideration in lieu of cash of deferred compensation for service as a member of the issuer's board of directors from the first quarter of 2023 through the first quarter of 2024, as disclosed in the Form 4 filed with the Securities and Exchange Commission (the \"SEC\") on April 17, 2024. This grant was approved in advance by the issuer's board of directors in accordance with Rule 16b-3 under the Securities Exchange Act of 1934 and is exempt from Section 16(b)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":6151,"source":{"system":"sec-edgar","filing":"0001104659-25-089066","document":"tm2525773-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465925089066/tm2525773-1_4seq1.xml","form_type":"4"}},{"id":1097122,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:05:31.000Z","date":"2025-05-27","kind":"grant","planned":false,"acquired":true,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share."},{"field":"shares","element":"transactionShares","label":"F1","text":"On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share."}],"balance_after":1100,"derivative":{"exercise_price":6.4,"expiration_date":"2035-05-26","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0000950170-25-092938","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017025092938/ownership.xml","form_type":"4"}},{"id":1128646,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T21:09:45.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":9326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."}],"balance_after":9326,"derivative":{"exercise_price":0.4454,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9326},"source":{"system":"sec-edgar","filing":"0001213900-25-050131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390025050131/ownership.xml","form_type":"4"}},{"id":1170657,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T21:01:38.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":2232,"price":5.6,"value":12499.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"2,232 shares of common stock were granted upon the close of business on April 15, 2025, as a consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q1-25."}],"balance_after":12303,"source":{"system":"sec-edgar","filing":"0001104659-25-036084","document":"tm2512512-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465925036084/tm2512512-2_4seq1.xml","form_type":"4"}},{"id":1220949,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-06T21:18:14.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":17923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."}],"balance_after":17923,"derivative":{"exercise_price":1.43,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":17923},"source":{"system":"sec-edgar","filing":"0001213900-25-021192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390025021192/ownership.xml","form_type":"4"}},{"id":1242092,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:01:11.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":12767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":12767,"derivative":{"exercise_price":2.54,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":12767},"source":{"system":"sec-edgar","filing":"0000950170-25-028268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017025028268/ownership.xml","form_type":"4"}},{"id":1242091,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:01:11.000Z","date":"2025-02-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.82,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":12767},"source":{"system":"sec-edgar","filing":"0000950170-25-028268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017025028268/ownership.xml","form_type":"4"}},{"id":1242090,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:01:11.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":1947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":1947,"derivative":{"exercise_price":2.54,"expiration_date":"2031-12-16","underlying":"Common Stock","underlying_shares":1947},"source":{"system":"sec-edgar","filing":"0000950170-25-028268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017025028268/ownership.xml","form_type":"4"}},{"id":1242089,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:01:11.000Z","date":"2025-02-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.29,"expiration_date":"2031-12-16","underlying":"Common Stock","underlying_shares":1947},"source":{"system":"sec-edgar","filing":"0000950170-25-028268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017025028268/ownership.xml","form_type":"4"}},{"id":1242088,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:01:11.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":5431,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":5431,"derivative":{"exercise_price":2.54,"expiration_date":"2031-09-16","underlying":"Common Stock","underlying_shares":5431},"source":{"system":"sec-edgar","filing":"0000950170-25-028268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017025028268/ownership.xml","form_type":"4"}},{"id":1242087,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:01:11.000Z","date":"2025-02-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5431,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.29,"expiration_date":"2031-09-16","underlying":"Common Stock","underlying_shares":5431},"source":{"system":"sec-edgar","filing":"0000950170-25-028268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017025028268/ownership.xml","form_type":"4"}},{"id":1244871,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T23:02:04.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 127,500 shares."}],"balance_after":255000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-25-017518","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390025017518/ownership.xml","form_type":"4"}},{"id":1283134,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T21:01:05.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 56,400 shares of the Issuer's Common Stock, which will vest in full on February 1, 2026, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":56400,"derivative":{"exercise_price":9.6,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0000950170-25-014438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017025014438/ownership.xml","form_type":"4"}},{"id":1302099,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-16T22:18:49.000Z","date":"2025-01-14","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance."}],"balance_after":1000,"derivative":{"exercise_price":6.06,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-25-004170","document":"tm253548-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465925004170/tm253548-9_4seq1.xml","form_type":"4"}},{"id":1343968,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-05T02:12:09.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On December 2, 2024, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 127,500 shares."}],"balance_after":127500,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-24-105728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024105728/ownership.xml","form_type":"4"}},{"id":1395883,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-10-03T01:53:38.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":false,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":965997},"source":{"system":"sec-edgar","filing":"0001213900-24-084831","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024084831/ownership.xml","form_type":"4"}},{"id":1395882,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T01:53:38.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":true,"shares":965997,"ownership":{"direct":false,"nature":"By the Kathleen LaPorte Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the trustee of the Kathleen LaPorte Revocable Trust (the \"Trust\") and has sole voting and disposition power with respect to the shares owned by the Trust."}],"balance_after":965997,"source":{"system":"sec-edgar","filing":"0001213900-24-084831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024084831/ownership.xml","form_type":"4"}},{"id":1413342,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":2000,"derivative":{"exercise_price":6.56,"expiration_date":"2032-01-11","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413341,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":30.8,"expiration_date":"2032-01-11","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413340,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":1250,"derivative":{"exercise_price":6.56,"expiration_date":"2031-03-08","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413339,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":64.4,"expiration_date":"2031-03-08","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413338,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":1250,"derivative":{"exercise_price":6.56,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413337,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":42,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413336,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":200,"derivative":{"exercise_price":6.56,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413335,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":26,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413334,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":375,"derivative":{"exercise_price":6.56,"expiration_date":"2030-01-16","underlying":"Common Stock","underlying_shares":375},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413333,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":42.8,"expiration_date":"2030-01-16","underlying":"Common Stock","underlying_shares":375},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413332,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":70,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":70,"derivative":{"exercise_price":6.56,"expiration_date":"2029-04-17","underlying":"Common Stock","underlying_shares":70},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413331,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":123,"expiration_date":"2029-04-17","underlying":"Common Stock","underlying_shares":70},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413330,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":28,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":28,"derivative":{"exercise_price":6.56,"expiration_date":"2029-04-17","underlying":"Common Stock","underlying_shares":28},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413329,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":123,"expiration_date":"2029-04-17","underlying":"Common Stock","underlying_shares":28},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413328,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":250,"derivative":{"exercise_price":6.56,"expiration_date":"2029-03-18","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413327,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":45,"expiration_date":"2029-03-18","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413326,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":188,"derivative":{"exercise_price":6.56,"expiration_date":"2028-08-07","underlying":"Common Stock","underlying_shares":188},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413325,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":129,"expiration_date":"2028-08-07","underlying":"Common Stock","underlying_shares":188},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413324,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":75,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":75,"derivative":{"exercise_price":6.56,"expiration_date":"2028-08-07","underlying":"Common Stock","underlying_shares":75},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1413323,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T21:10:26.000Z","date":"2024-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 31, 2024 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the \"2017 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":129,"expiration_date":"2028-08-07","underlying":"Common Stock","underlying_shares":75},"source":{"system":"sec-edgar","filing":"0001104659-24-097789","document":"tm2423539-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924097789/tm2423539-5_4seq1.xml","form_type":"4"}},{"id":1470134,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-25T21:15:08.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance"}],"balance_after":1000,"derivative":{"exercise_price":4.98,"expiration_date":"2034-06-21","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-24-074810","document":"tm2418227-7_4seq.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924074810/tm2418227-7_4seq.xml","form_type":"4"}},{"id":1480039,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T22:52:57.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":22000,"derivative":{"exercise_price":0.7682,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-24-073889","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017024073889/ownership.xml","form_type":"4"}},{"id":1540785,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-17T20:26:16.000Z","date":"2024-04-15","kind":"grant","planned":false,"acquired":true,"shares":9693,"price":6.7,"value":64943.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"9,693 shares of common stock were granted upon the close of business on April 15, 2024, as a consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors for Q1-23 to Q4-23 and Q1-24. The price reported in Column 4 is a weighted average price ranging from $5.35 to $6.74. The reporting person undertakes to provide, upon request, full information regarding the number of shares calculated at each separate price within the range set forth in this footnote."}],"balance_after":10071,"source":{"system":"sec-edgar","filing":"0001104659-24-048332","document":"tm2412083-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465924048332/tm2412083-7_4seq1.xml","form_type":"4"}},{"id":1560067,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-28T01:28:26.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":112500,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001213900-24-026822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024026822/ownership.xml","form_type":"4"}},{"id":1560066,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T21:35:49.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":12767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":12767,"derivative":{"exercise_price":16.82,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":12767},"source":{"system":"sec-edgar","filing":"0000950170-24-037387","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017024037387/ownership.xml","form_type":"4"}},{"id":1631712,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-21T22:57:09.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":false,"nature":"By the Kathleen LaPorte Revocable Trust"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the trustee of the Kathleen LaPorte Revocable Trust (the \"Kathleen Trust\") and has sole voting and disposition power with respect to the shares owned by the Kathleen Trust."}],"balance_after":50,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001213900-24-015876","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024015876/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-16"}},{"id":1640070,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-17T00:37:58.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."}],"balance_after":50,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001213900-24-015027","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024015027/ownership.xml","form_type":"4"}},{"id":1640069,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-17T00:37:58.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":5828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock, distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock, distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."}],"balance_after":5828,"source":{"system":"sec-edgar","filing":"0001213900-24-015027","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024015027/ownership.xml","form_type":"4"}},{"id":1660329,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-06T01:11:31.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":45150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 45,150 shares of the Issuer's Common Stock, which will vest in full on February 1, 2025, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":45150,"derivative":{"exercise_price":9.98,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":45150},"source":{"system":"sec-edgar","filing":"0000950170-24-011467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017024011467/ownership.xml","form_type":"4"}},{"id":1781614,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-14T20:41:03.000Z","date":"2023-09-12","kind":"grant","planned":false,"acquired":true,"shares":7575,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The 7,575 restricted shares of common stock were granted upon the close of business on September 12, 2023 and vested immediately upon issuance.  The restricted shares were issued as consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors."}],"balance_after":7575,"source":{"system":"sec-edgar","filing":"0001104659-23-100815","document":"tm2326171-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465923100815/tm2326171-5_4seq1.xml","form_type":"4"}},{"id":1828353,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-18T22:04:56.000Z","date":"2023-07-17","kind":"exercise","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is vested in full."}],"balance_after":12500,"derivative":{"exercise_price":2.64,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-23-033420","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017023033420/ownership.xml","form_type":"4"}},{"id":1828352,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-18T22:04:56.000Z","date":"2023-07-17","kind":"sale","planned":false,"acquired":false,"shares":12500,"price":18.8,"value":235000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $18.77 to $18.90. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-23-033420","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017023033420/ownership.xml","form_type":"4"}},{"id":1828351,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-18T22:04:56.000Z","date":"2023-07-17","kind":"exercise","planned":false,"acquired":true,"shares":12500,"price":2.64,"value":33000.0,"ownership":{"direct":true},"balance_after":12500,"source":{"system":"sec-edgar","filing":"0000950170-23-033420","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000095017023033420/ownership.xml","form_type":"4"}},{"id":1856683,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T21:15:00.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":1.63,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-037107","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000120919123037107/doc4.xml","form_type":"4"}},{"id":2021578,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-13T22:35:31.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 27,400 shares of the Issuer's Common Stock, which will vest in full on February 9, 2024, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":27400,"derivative":{"exercise_price":14.7,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0000899243-23-004800","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000089924323004800/doc4.xml","form_type":"4"}},{"id":2058188,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-10T21:44:49.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance"}],"balance_after":30000,"derivative":{"exercise_price":0.62,"expiration_date":"2033-01-06","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-23-002766","document":"tm233036-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465923002766/tm233036-5_4seq1.xml","form_type":"4"}},{"id":2084578,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-16T18:18:39.000Z","date":"2022-12-14","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall be fully vested upon grant date of December 14, 2022."}],"balance_after":25000,"derivative":{"exercise_price":1.36,"exercise_date":"2022-12-14","expiration_date":"2032-12-13","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-061587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000120919122061587/doc4.xml","form_type":"4"}},{"id":2237013,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T22:15:28.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest on the one-year anniversary of June 10, 2022 (the \"Vesting Commencement Date\") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":1.99,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-036079","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000120919122036079/doc4.xml","form_type":"4"}},{"id":2267067,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-18T20:06:01.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, which will vest in full on May 16, 2023, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-018593","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000089924322018593/doc4.xml","form_type":"4"}},{"id":2317318,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-28T19:22:39.000Z","date":"2022-03-24","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest on the one-year anniversary of June 10, 2021 (the \"Vesting Commencement Date\") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":3.03,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-012464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000089924322012464/doc4.xml","form_type":"4"}},{"id":2436396,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-13T22:09:34.000Z","date":"2022-01-11","kind":"grant","acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance"}],"balance_after":40000,"derivative":{"exercise_price":1.54,"expiration_date":"2032-01-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-22-004067","document":"tm222906-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465922004067/tm222906-9_4seq1.xml","form_type":"4"}},{"id":2527950,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-03T20:36:41.000Z","date":"2021-11-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, which will vest in equal installments on November 1, 2022, November 1, 2023 and November 1, 2024, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":18.68,"expiration_date":"2031-11-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-21-042740","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000089924321042740/doc4.xml","form_type":"4"}},{"id":2545131,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2021-10-12T23:28:05.000Z","date":"2021-10-08","kind":"other","acquired":true,"shares":17500,"ownership":{"direct":false,"nature":"By Phoenix Biotech Sponsor, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC, for service on the issuer's board of directors."},{"field":"shares","element":"transactionShares","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC, for service on the issuer's board of directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date."}],"balance_after":17500,"derivative":{"underlying":"Class A Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000899243-21-039932","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000089924321039932/doc4.xml","form_type":"4"}},{"id":2613956,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (Right to Buy)","published_at":"2021-08-05T21:43:33.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance"}],"balance_after":25000,"derivative":{"exercise_price":3.22,"expiration_date":"2031-08-03","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-21-100870","document":"tm2124311-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465921100870/tm2124311-7_4seq1.xml","form_type":"4"}},{"id":2873650,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:35:34.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":1200,"price":20,"value":24000.0,"ownership":{"direct":true},"balance_after":1200,"source":{"system":"sec-edgar","filing":"0001209191-21-008756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000120919121008756/doc4.xml","form_type":"4"}},{"id":2924202,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-05T21:32:38.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance"}],"balance_after":25000,"derivative":{"exercise_price":2.1,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-21-000964","document":"tm211613-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465921000964/tm211613-5_4seq1.xml","form_type":"4"}},{"id":3090346,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-06T20:32:41.000Z","date":"2020-07-02","kind":"grant","acquired":true,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance"}],"balance_after":4000,"derivative":{"exercise_price":1.3,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-20-081247","document":"tm2024163d7_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465920081247/tm2024163d7_4.xml","form_type":"4"}},{"id":3307095,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-21T20:22:33.000Z","date":"2020-01-16","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance"}],"balance_after":7500,"derivative":{"exercise_price":2.14,"expiration_date":"2030-01-16","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-20-005500","document":"tm205425-2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000110465920005500/tm205425-2_4.xml","form_type":"4"}},{"id":3551865,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-22T20:00:53.000Z","date":"2019-04-17","kind":"grant","acquired":true,"shares":21163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest as follows: shall vest in 26 equal monthly installments"}],"balance_after":21163,"derivative":{"exercise_price":0.41,"expiration_date":"2028-08-06","underlying":"Common Stock","underlying_shares":21123},"source":{"system":"sec-edgar","filing":"0001144204-19-020552","document":"tv519332_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000114420419020552/tv519332_4.xml","form_type":"4"}},{"id":3551864,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-22T20:00:53.000Z","date":"2019-04-17","kind":"grant","acquired":true,"shares":8465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest as follows: shall vest in 4 equal monthly installments."}],"balance_after":8465,"derivative":{"exercise_price":0.41,"expiration_date":"2028-08-06","underlying":"Common Stock","underlying_shares":8465},"source":{"system":"sec-edgar","filing":"0001144204-19-020552","document":"tv519332_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000114420419020552/tv519332_4.xml","form_type":"4"}},{"id":3585473,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-20T21:00:21.000Z","date":"2019-03-18","kind":"grant","acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance"}],"balance_after":75000,"derivative":{"exercise_price":0.15,"expiration_date":"2029-03-18","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001144204-19-015162","document":"tv516768_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000114420419015162/tv516768_4.xml","form_type":"4"}},{"id":3846926,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-13T22:41:34.000Z","date":"2018-08-07","kind":"grant","acquired":true,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest as follows:  shall vest in 36 equal monthly installments."}],"balance_after":56400,"derivative":{"exercise_price":0.43,"expiration_date":"2028-08-06","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0000899243-18-022168","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000089924318022168/doc4.xml","form_type":"4"}},{"id":3846925,"issuer":{"id":7207,"kind":"organization","name":"Precipio, Inc."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-13T22:41:34.000Z","date":"2018-08-07","kind":"grant","acquired":true,"shares":22560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest as follows:  shall vest in 36 equal monthly installments."}],"balance_after":22560,"derivative":{"exercise_price":0.43,"expiration_date":"2028-08-06","underlying":"Common Stock","underlying_shares":22560},"source":{"system":"sec-edgar","filing":"0000899243-18-022168","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000089924318022168/doc4.xml","form_type":"4"}}]}